A two-years real-word study with fingolimod: early predictors of efficacy and an association between EBNA-1 IgG titers and multiple sclerosis progression.

ABSTRACT:

Background

Although fingolimod, a sphingosine 1-phosphate receptor agonist, has shown to be an effective treatment reducing relapse rate and also slowing down the disability progression in relapsing-remitting multiple sclerosis (RRMS) patients, it is important to quickly identify those suboptimal responders.

Objective

The main objective was to assess different clinical, radiological, genetic and environmental factors as possible early predictors of response in MS patients treated with fingolimod for 24 months. The secondary objective was to analyze the possible contribution of the environmental factors analyzed to the progression and activity of the disease along the 2-years of follow-up.

Methods

A retrospective study with 151 patients diagnosed with MS, under fingoli

SUBMITTER: Dominguez-Mozo MI 

PROVIDER: S-EPMC11190074 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature